AU2005205531B2 - Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders - Google Patents

Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders Download PDF

Info

Publication number
AU2005205531B2
AU2005205531B2 AU2005205531A AU2005205531A AU2005205531B2 AU 2005205531 B2 AU2005205531 B2 AU 2005205531B2 AU 2005205531 A AU2005205531 A AU 2005205531A AU 2005205531 A AU2005205531 A AU 2005205531A AU 2005205531 B2 AU2005205531 B2 AU 2005205531B2
Authority
AU
Australia
Prior art keywords
alkyl
amino
compound
composition
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005205531A
Other languages
English (en)
Other versions
AU2005205531A1 (en
Inventor
Cyrus Becker
Pascal Druzgala
Ian Irwin
Monica Palme
Courtney Rubens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renexxion LLC
Original Assignee
Renexxion LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renexxion LLC filed Critical Renexxion LLC
Publication of AU2005205531A1 publication Critical patent/AU2005205531A1/en
Priority to AU2008243243A priority Critical patent/AU2008243243B2/en
Application granted granted Critical
Publication of AU2005205531B2 publication Critical patent/AU2005205531B2/en
Assigned to ARMETHEON, INC. reassignment ARMETHEON, INC. Request for Assignment Assignors: ARYX THERAPEUTICS
Assigned to RENEXXION, LLC reassignment RENEXXION, LLC Request to Amend Deed and Register Assignors: ARMETHEON, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005205531A 2004-01-07 2005-01-07 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders Expired AU2005205531B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008243243A AU2008243243B2 (en) 2004-01-07 2008-11-13 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53489204P 2004-01-07 2004-01-07
US60/534,892 2004-01-07
US56093804P 2004-04-09 2004-04-09
US60/560,938 2004-04-09
PCT/US2005/000510 WO2005068461A1 (en) 2004-01-07 2005-01-07 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008243243A Division AU2008243243B2 (en) 2004-01-07 2008-11-13 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Publications (2)

Publication Number Publication Date
AU2005205531A1 AU2005205531A1 (en) 2005-07-28
AU2005205531B2 true AU2005205531B2 (en) 2011-03-17

Family

ID=34798839

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005205531A Expired AU2005205531B2 (en) 2004-01-07 2005-01-07 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
AU2008243243A Expired AU2008243243B2 (en) 2004-01-07 2008-11-13 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008243243A Expired AU2008243243B2 (en) 2004-01-07 2008-11-13 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Country Status (19)

Country Link
US (2) US7176218B2 (enExample)
EP (2) EP2194053B1 (enExample)
JP (2) JP5200288B2 (enExample)
KR (1) KR101240464B1 (enExample)
CN (1) CN101824033B (enExample)
AT (1) ATE464308T1 (enExample)
AU (2) AU2005205531B2 (enExample)
BR (1) BRPI0506736B1 (enExample)
CA (1) CA2551686C (enExample)
CY (1) CY1110901T1 (enExample)
DE (1) DE602005020580D1 (enExample)
DK (2) DK2194053T3 (enExample)
ES (2) ES2415830T3 (enExample)
IL (1) IL176569A (enExample)
MX (1) MXPA06007853A (enExample)
NO (1) NO337741B1 (enExample)
PT (2) PT1704146E (enExample)
RU (1) RU2374244C2 (enExample)
WO (1) WO2005068461A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
ES2415830T3 (es) * 2004-01-07 2013-07-29 Armetheon, Inc. Derivados de metoxipiperidina para la utilización en el tratamiento de los trastornos gastrointestinales y del sistema nervioso central
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2007028073A2 (en) * 2005-08-31 2007-03-08 Aryx Therapeutics, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
CN101258151B (zh) * 2005-08-31 2012-10-10 ARYx医疗有限公司 用于治疗胃肠系统和中枢神经系统疾病的立体异构化合物的合成方法及中间体
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
KR20080080214A (ko) * 2005-12-23 2008-09-02 아스트라제네카 아베 헤테로시클릭 ｇａｂａ-ｂ 조절제
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CN101402633A (zh) 2007-09-11 2009-04-08 上海恒瑞医药有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
WO2010062959A1 (en) * 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
PL395470A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
TWI710372B (zh) * 2014-05-16 2020-11-21 日商拉夸里亞創藥股份有限公司 用於胃輕癱之5-ht4受體激動劑
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
WO2016138176A1 (en) 2015-02-24 2016-09-01 Elira Therapeutics Llc Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US20220062621A1 (en) 2015-02-24 2022-03-03 Elira, Inc. Electrical Stimulation-Based Weight Management System
US11495028B2 (en) * 2018-09-28 2022-11-08 Intel Corporation Obstacle analyzer, vehicle control system, and methods thereof
TW202024081A (zh) * 2018-11-05 2020-07-01 美商瑞內克松有限公司 生產三水合那羅普來得(naronapride)之方法
US10570127B1 (en) * 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB1425706A (en) 1972-06-30 1976-02-18 Wyeth John & Brother Ltd Piperidine derivatives
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
GB8519707D0 (en) * 1985-08-06 1985-09-11 Fordonal Sa Chemical compounds
SK289787A3 (en) * 1986-04-30 1998-06-03 Dainippon Pharmaceutical Co Substituted n-£(2-morpholinyl)alkyl|benzamide derivative, method of producing the same and a pharmaceutical composition on its base
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5041454A (en) * 1987-09-25 1991-08-20 Janssen Pharmaceutica N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
JP3104142B2 (ja) * 1991-02-15 2000-10-30 北陸製薬株式会社 ベンズアミド誘導体
TW213460B (enExample) * 1991-02-15 1993-09-21 Hokuriku Pharmaceutical
US5395832A (en) * 1991-02-15 1995-03-07 Hokuriku Seiyaku Co., Ltd. Benzamide derivatives
IT1260485B (it) * 1992-05-29 1996-04-09 Procedimento e dispositivo per il trattamento dell'obesita' di un paziente
EP0649307A4 (en) * 1992-07-07 1996-06-26 Sepracor Inc METHOD FOR USING (-) - CISAPRIDE FOR TREATING GASTIC EYE ELEMENTS AND OTHER DISEASES.
WO1994001111A1 (en) * 1992-07-07 1994-01-20 Sepracor Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
AU680453B2 (en) 1992-11-05 1997-07-31 Smithkline Beecham Plc Piperidine derivatives as 5-HT4 receptor antagonists
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
US5705798A (en) * 1994-12-16 1998-01-06 Mastercard International Inc. System and method for processing a customized financial transaction card
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
PL190296B1 (pl) 1997-07-11 2005-11-30 Janssen Pharmaceutica Nv Zastosowanie (+)-norcyzaprydu
JPH11292846A (ja) 1998-02-10 1999-10-26 Hokuriku Seiyaku Co Ltd ベンズアミド誘導体及びそれを含有する医薬
AR022338A1 (es) 1999-02-04 2002-09-04 Hokuriku Pharmaceutical Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
JP2004513071A (ja) 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法
WO2001093849A2 (en) 2000-06-07 2001-12-13 Aryx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
ES2415830T3 (es) * 2004-01-07 2013-07-29 Armetheon, Inc. Derivados de metoxipiperidina para la utilización en el tratamiento de los trastornos gastrointestinales y del sistema nervioso central

Also Published As

Publication number Publication date
WO2005068461A1 (en) 2005-07-28
BRPI0506736B1 (pt) 2018-08-21
JP5524939B2 (ja) 2014-06-18
CN101824033A (zh) 2010-09-08
CA2551686A1 (en) 2005-07-28
US7176218B2 (en) 2007-02-13
RU2006128589A (ru) 2008-02-20
EP2194053A1 (en) 2010-06-09
US7282509B2 (en) 2007-10-16
EP2194053B1 (en) 2013-03-27
PT2194053E (pt) 2013-07-08
US20050176757A1 (en) 2005-08-11
BRPI0506736A (pt) 2007-05-15
KR101240464B1 (ko) 2013-03-08
IL176569A0 (en) 2006-10-31
EP1704146B1 (en) 2010-04-14
EP1704146A1 (en) 2006-09-27
JP5200288B2 (ja) 2013-06-05
CN101824033B (zh) 2013-02-27
CY1110901T1 (el) 2015-06-10
AU2008243243A1 (en) 2008-12-04
JP2012102102A (ja) 2012-05-31
PT1704146E (pt) 2010-06-30
CA2551686C (en) 2014-09-23
ES2415830T3 (es) 2013-07-29
JP2007517891A (ja) 2007-07-05
AU2005205531A1 (en) 2005-07-28
NO337741B1 (no) 2016-06-13
RU2374244C2 (ru) 2009-11-27
ES2344568T3 (es) 2010-08-31
DE602005020580D1 (de) 2010-05-27
KR20060128966A (ko) 2006-12-14
BRPI0506736B8 (enExample) 2021-05-25
US20050197363A1 (en) 2005-09-08
IL176569A (en) 2011-06-30
DK1704146T3 (da) 2010-06-28
AU2008243243B2 (en) 2011-03-10
DK2194053T3 (da) 2013-07-01
NO20063568L (no) 2006-08-07
MXPA06007853A (es) 2007-01-26
ATE464308T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
AU2005205531B2 (en) Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US7629466B2 (en) Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP1907376A2 (en) Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CN1918157B (zh) 立体异构化合物及治疗胃肠道和中枢神经系统紊乱的方法
CN101258151A (zh) 用于治疗胃肠系统和中枢神经系统疾病的立体异构化合物的合成方法及中间体
HK1180680A (en) Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
HK1121762B (en) Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-INVENTOR DRUZGALA, PASCAL AND RUBENS, COURTNEY

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ARMETHEON, INC.

Free format text: FORMER OWNER WAS: ARYX THERAPEUTICS

HB Alteration of name in register

Owner name: RENEXXION, LLC

Free format text: FORMER NAME(S): ARMETHEON, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired